Products

• History of Brachytherapy
• Prostate Treatment
• Lung Treatment
• Ocular Treatment

Lung Cancer Treatment

A significant portion of Stage 1 NSCLC patients will present with significant pulmonary function compromise. This subset of patients may benefit from lung brachytherapy. (C. Fernando, R. S. Santos, J. R. Benfield, F. W. Grannis, R. J. Keenan, J. D. Luketich, J. M. Close, and R. J. Landreneau. "Lobar and sublobar resection with and without brachytherapy for small stage 1A and non-small cell lung cancer." J. Thorac. Cardiovasc. Surg. 129, 261-267 (2005).)

Deliver the dose where you want. When it's needed.

• Cesium-131 has delivered 90% of the intended dose 33 days post implant, compared to 32% of the I-125 dose.
• Cesium-131 has delivered 99.8% of the dose at 90 days, when the sutures/mesh have most likely dissolved, compared to 65% for I-125.
• Once the carrier material has dissolved, the seeds are free to migrate and stop contributing to the prescription dose plan.
• Cesium-131 delivers uniform and symmetrical radiation penetration for a homogeneous lung implant.

Facts & Figures

• In 2009 an estimated 219,440 cases of lung cancer will be diagnosed.
• 159,390 deaths attributable to lung cancer will occur in the U.S. (A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun. "Cancer Statistics 2009." CA Cancer J. Clin. 59, 225-249 (2009).)
• Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer diagnoses in the U.S. (W. D. Travis, L. B. Travis, and S. S. Devesa. "Lung cancer." Cancer 75 (1 Suppl), 191-202 (1995).)
• Thus, it is anticipated that approximately 160,000 cases of NSCLC will be diagnosed and treated in the U.S. in 2009.
• A report by Ravdin and Davis based on SEER data reveals that five-year survival following surgical resection of Stage 1 NSCLC stands at 70%. (P. M. Ravdin and G. Davis. "Prognosis of patients with resected non-small cell lung cancer: Impact of clinical and pathologic variables." Lung Cancer 52(2), 207-212 (2006).)